Viral Protein Patents (Class 536/23.72)
  • Patent number: 8491916
    Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: July 23, 2013
    Assignees: The United States of America as represented by the Secretary of Agriculture, Boehringer Ingelheim Vetmedica, Inc.
    Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
  • Patent number: 8492533
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: July 23, 2013
    Assignee: Zoetis LLC
    Inventors: Jay Gregory Calvert, Michael G. Sheppard, Siao-Kun W. Welch, Raymond R. R. Rowland, Dal-Young Kim
  • Patent number: 8492132
    Abstract: The invention provides isolated polynucleotide molecules, plasmids, viral vectors, and transfected host cells that comprise a DNA molecule encoding an infectious RNA molecule that encode a PRRS (Porcine Reproductive and Respiratory Syndrome) virus, and further provides the PRRS virus encoded thereby. The invention also provides isolated infectious RNA molecules encoding PRRS virus.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: July 23, 2013
    Assignee: Zoetis LLC
    Inventors: Jay G. Calvert, Michael G. Shepard, Siao-Kun W. Welch
  • Publication number: 20130183754
    Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.
    Type: Application
    Filed: January 3, 2013
    Publication date: July 18, 2013
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, TORAY INDUSTRIES, INC.
    Inventors: Toray Industries, Inc., Tokyo Metropolitan Institute Of Medical Science, Ralf Bartenschlager
  • Publication number: 20130183342
    Abstract: Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. It is disclosed herein that influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.
    Type: Application
    Filed: September 9, 2011
    Publication date: July 18, 2013
    Inventors: Ted M. Ross, Brendan M. Giles
  • Publication number: 20130183689
    Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.
    Type: Application
    Filed: November 21, 2012
    Publication date: July 18, 2013
    Applicant: HYGLOS INVEST GMBH
    Inventor: HYGLOS INVEST GMBH
  • Publication number: 20130183329
    Abstract: Provided are polynucleotides and proteins encoded by them which are useful for stimulating an immune response against Porcine reproductive and respiratory syndrome virus (PRRSV) in swine. The compositions can contain a newly discovered PRRSV strain or recombinant versions of it or polynucleotides isolated or derived from it, which can be provided as pharmaceutical preparations.
    Type: Application
    Filed: December 3, 2012
    Publication date: July 18, 2013
    Inventors: Yanjin Zhang, Yuchen Nan
  • Patent number: 8486418
    Abstract: The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: July 16, 2013
    Assignees: Merial Limited, University of Georgia Research Foundation, Inc.
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Egburt Mundt
  • Publication number: 20130177582
    Abstract: The invention describes a therapeutic agent capable of treating and/or preventing rabbit haemorrhagic disease virus infection in rabbits, namely a recombinant parapoxvirus, characterized in that the VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV) is expressed from a foreign nucleic acid.
    Type: Application
    Filed: April 29, 2011
    Publication date: July 11, 2013
    Applicant: RIEMSER ARZNEIMITTEL AG
    Inventor: Hanns-Joachim Rziha
  • Publication number: 20130177583
    Abstract: The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection.
    Type: Application
    Filed: March 3, 2011
    Publication date: July 11, 2013
    Applicants: Duke University, The UAB Research Foundation
    Inventors: George M. Shaw, Beatrice H. Hahn, Hui Li, Barton F. Haynes, Martin Markowitz
  • Patent number: 8481705
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 9, 2013
    Assignee: Zoetis LLC
    Inventors: Jay Gregory Calvert, Michael G. Sheppard, Siao-Kun W. Welch, Raymond R. R. Rowland, Dal-Young Kim
  • Publication number: 20130171150
    Abstract: The invention is directed to a Feline Picorna Virus, an isolated nucleic acid and amino acid sequences therefrom, and uses thereof.
    Type: Application
    Filed: July 19, 2012
    Publication date: July 4, 2013
    Inventors: Amit Kapoor, Edward J. Dubovi, W. Ian Lipkin
  • Publication number: 20130171234
    Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
    Type: Application
    Filed: February 25, 2011
    Publication date: July 4, 2013
    Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
  • Publication number: 20130171182
    Abstract: The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface polypeptide M2 or a fragment thereof in the e1 loop.
    Type: Application
    Filed: October 22, 2010
    Publication date: July 4, 2013
    Applicant: iQUR Limited
    Inventors: Michael Anthony Whelan, William Malcolm Rosenberg, Lucy Phillipa Beales
  • Publication number: 20130172209
    Abstract: The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.
    Type: Application
    Filed: January 11, 2013
    Publication date: July 4, 2013
    Applicant: BIOMERIEUX
    Inventor: BIOMERIEUX
  • Publication number: 20130164306
    Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
    Type: Application
    Filed: November 15, 2012
    Publication date: June 27, 2013
    Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventor: SANFORD-BURNHAM MEDICAL RESEARCH IN
  • Publication number: 20130164326
    Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.
    Type: Application
    Filed: June 25, 2012
    Publication date: June 27, 2013
    Applicant: Vaxart, Inc.
    Inventor: Sean N. Tucker
  • Publication number: 20130164316
    Abstract: The present invention relates, in general, to HIV-1 and, in particular, to immunogens that elicit broadly neutralizing antibodies against HIV-1 subtype C envelope glycoproteins, and compositions comprising same. The invention further relates to methods of inducing the production of such antibodies in a subject.
    Type: Application
    Filed: November 7, 2012
    Publication date: June 27, 2013
    Applicants: Los Alamos National Security, LLC, Duke University
    Inventors: Duke University, Los Alamos National Security, LLC
  • Patent number: 8470334
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: June 25, 2013
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W. Barnett, Indresh K. Srivastava
  • Publication number: 20130158246
    Abstract: A modified CAG promoter which is capable of driving high levels of expression of sequences of interest inserted downstream therefrom is herein described.
    Type: Application
    Filed: August 7, 2009
    Publication date: June 20, 2013
    Inventors: Gary Kobinger, Heinz Feldmann, Kaylie Tran
  • Patent number: 8465748
    Abstract: The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: June 18, 2013
    Inventor: Matthias Giese
  • Publication number: 20130149323
    Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 7, 2012
    Publication date: June 13, 2013
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, VIROXIS S.A.S., INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SUD XI
    Inventors: Centre National De La Recherche Scientifique, Universite Paris-Sud XI, Institut Gustave Roussy, Viroxis S.A.S.
  • Publication number: 20130149334
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Application
    Filed: October 7, 2011
    Publication date: June 13, 2013
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Publication number: 20130149336
    Abstract: The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention. In another embodiment, the invention provides novel methods of identifying a cryptic neutralizing epitope and related vaccines, constructs, and libraries. In some embodiments, these methods use high-throughput formats that are facilitated by in silica or in vitro steps.
    Type: Application
    Filed: October 26, 2012
    Publication date: June 13, 2013
    Inventors: Brian L. Hjelle, David S. Peabody, Bryce Chackerian
  • Patent number: 8460912
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: June 11, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Publication number: 20130142824
    Abstract: The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 6, 2013
    Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
    Inventors: Yanyan Ni, Yao-Wei Huang, Xiang-Jin Meng
  • Publication number: 20130142764
    Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.
    Type: Application
    Filed: October 15, 2012
    Publication date: June 6, 2013
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: University of Iowa Research Foundation
  • Patent number: 8454972
    Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 4, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.
    Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
  • Patent number: 8454974
    Abstract: The present inventors developed three 4a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 4a reference strain ED43. The 4a/2a junction in NS2 was placed after the first transmembrane domain (?), in the cytoplasmic part (?) or at the NS2/NS3 cleavage site (y). Following transfection of Huh7.5 cells with RNA transcripts, infectious viruses were produced in the ED43/JFH1-? and -y cultures only. Compared to the 2a control virus, production of infectious viruses was significantly delayed. However, in subsequent passages efficient spread of infection and high HCV RNA titers were obtained. Infectivity titers were approximately 10-fold lower than for the 2a control virus. Sequence analysis of recovered 4a/2a recombinants from 3 serial passages and subsequent reverse genetic studies revealed a vital dependence on a mutation in the NS2 4a part. ED43/JFH1-? further depended on a second NS2 mutation.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: June 4, 2013
    Assignee: Hvidovre Hospital
    Inventors: Troels Kasper Høyer Scheel, Judith M. Gottwein, Jesper Eugen-Olsen, Jens Bukh
  • Patent number: 8454973
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 4, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Patent number: 8450289
    Abstract: The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: May 28, 2013
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offenlichen Rechts
    Inventors: Laurent Daeffler, Jurg Nuesch, Jean Rommelaere
  • Publication number: 20130129683
    Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.
    Type: Application
    Filed: May 9, 2011
    Publication date: May 23, 2013
    Applicant: Deutsches Krebforschungszentrum
    Inventors: Jürg Nüesch, Nadja Thomas, Claudia Plotzky, Jean Rommelaere
  • Publication number: 20130129761
    Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Application
    Filed: March 30, 2011
    Publication date: May 23, 2013
    Applicant: Mount Sinai School of Medicine
    Inventors: Adolfo Garcia-Sastre, Peter Palese, John Steel, Anice C. Lowen
  • Publication number: 20130130389
    Abstract: The problem to be solved by the present invention is to provide a highly-efficient transformation technology, specifically, a highly-efficient promoter used for transforming algae, a vector comprising the promoter, and a method for transforming algae by using the vector. The promoter according to the present invention is characterized in comprising a polynucleotide constituting a non-coding region located upstream of a gene encoding a structural protein of a ClorDNA virus, and the like.
    Type: Application
    Filed: February 10, 2011
    Publication date: May 23, 2013
    Applicant: KOCHI UNIVERSITY
    Inventors: Masao Adachi, Takuma Okami, Keizo Nagasaki, Yuji Tomaru
  • Patent number: 8445663
    Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: May 21, 2013
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Lars Frelin
  • Publication number: 20130123483
    Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 16, 2013
    Applicant: GENEART AG
    Inventors: DAVID RAAB, MARCUS GRAF, FRANK NOTKA, RALF WAGNER
  • Publication number: 20130115234
    Abstract: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.
    Type: Application
    Filed: March 28, 2011
    Publication date: May 9, 2013
    Applicant: Emergent Product Development Gaithersburg,Inc.
    Inventors: Tina Guina, Michael Lacy, Mario Skiadopoulos, Nutan Mytle
  • Publication number: 20130115235
    Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: October 4, 2012
    Publication date: May 9, 2013
    Applicant: MEDIMMUNE, LLC
    Inventor: MEDIMMUNE, LLC
  • Publication number: 20130115592
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 9, 2013
    Applicants: TORAY INDUSTRIES, INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Tokyo Metropolitan Institute Of Medical Science, Toray Industries, Inc.
  • Patent number: 8435732
    Abstract: A recombinant DNA construct, recombinant vectors and host cells comprising the dimers of DNA A and DNA B of Mungbean Yellow Mosaic India Virus (MYMIV) in a single Ti plasmid are provided herein.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: May 7, 2013
    Assignee: National Institute for Plant Genome Research
    Inventors: Debasis Chattopadhyay, Rajiv Kumar Yadav, Rakesh Kumar Shukla
  • Patent number: 8435731
    Abstract: Compositions and methods for the detection, diagnosis and treatment of BVDV are provided.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: May 7, 2013
    Assignees: Colorado State University Research Foundation, The University of Wyoming
    Inventors: Thomas R. Hansen, Natalia P. Smirnova, Kathleen J. Austin, Alberto van Olphen
  • Publication number: 20130109742
    Abstract: This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.
    Type: Application
    Filed: January 12, 2011
    Publication date: May 2, 2013
    Inventors: Curtis Hewitt, Richard Jude Samulski
  • Publication number: 20130111612
    Abstract: The invention relates to a non-human primate animal model for HBV infection, said animal model being of the Cercopithecidae family.
    Type: Application
    Filed: March 24, 2011
    Publication date: May 2, 2013
    Inventors: Isabelle Chemin, Christian Trepo
  • Publication number: 20130108658
    Abstract: The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.
    Type: Application
    Filed: October 11, 2012
    Publication date: May 2, 2013
    Applicants: MediGene AG, Universitaet Zu Koeln, Ludwig-Maximilians-Universitaet
    Inventor: MediGene AG
  • Publication number: 20130101618
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Application
    Filed: April 15, 2011
    Publication date: April 25, 2013
    Applicants: OKAIROS AG, TheGovernmentof the UnitedStatesof America asRepre -sentedby theSecretaryoftheDept.ofHealth&HumanSer
    Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 8426575
    Abstract: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: April 23, 2013
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Manuel V. Borca, Guillermo R. Risatti
  • Patent number: 8426188
    Abstract: The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: April 23, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Scott C. Weaver, Ilya V. Frolov, Elena Frolova
  • Patent number: 8426574
    Abstract: Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: April 23, 2013
    Assignees: Washington University, The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: David Wang, Herbert Whiting Virgin, IV, Guoyan Zhao, Stacy Finkbeiner, Jan Vinje, Yan Li, Suxiang Tong
  • Patent number: 8420389
    Abstract: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: April 16, 2013
    Assignee: Merial Limited
    Inventor: Jean Christophe Francis Audonnet
  • Publication number: 20130089558
    Abstract: The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
    Type: Application
    Filed: June 2, 2009
    Publication date: April 11, 2013
    Inventors: Frédéric Tangy, PHILIPPE DESPRES, CHANTAL COMBREDET, MARIE PASCALE FRENKIEL